OncoMatch/Clinical Trials/NCT05053867
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
Is NCT05053867 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies tranexamic acid for pulmonary hemorrhage.
Treatment: tranexamic acid — This is a drug study that will examine if inhaled tranexamic acid can improve mortality in patients with cancer-related pulmonary hemorrhage and respiratory failure as compared to usual care.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: inhaled tranexamic acid
Cannot have received: anti-fibrinolytic therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify